ArticleInternational urology and nephrology2026
Observation on the short-term efficacy of telitacicept in the treatment of primary IgA nephropathy.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimGiven the limitations of current Immunoglobulin A nephropathy (IgAN) therapies, this study sought to evaluate the short-term efficacy and safety of the novel agent Telitacicept, a dual inhibitor of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), in a real-world clinical setting.
methodsThis study employed a single-center, retrospective, self-controlled before-after design. Twelve patients with primary IgAN on stable background therapy comprising angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers (ACEI/ARB) and a sodium-glucose cotransporter 2 inhibitor (SGLT2i) received add-on Telitacicept treatment for 6 months. Data on 24-h urinary protein excretion (24hUP) and estimated glomerular filtration rate (eGFR) were collected at baseline, 3 months, and 6 months. Urinary red blood cell count and safety-related indicators were collected at baseline and 6 months. Efficacy and safety were assessed by comparing intra-individual data across these time points.
resultsAfter Telitacicept treatment, 24hUP decreased at 3 and 6 months with statistical significance (p = 0.016, 0.004, respectively). The median 24hUP decreased from 1.13 g/24 h (IQR 0.62-2.24) at baseline to 0.52 g/24 h (IQR 0.26-1.33) at 3 months and was maintained at 0.51 g/24 h (IQR 0.15-1.07) at 6 months, yielding a clinical remission rate of 75.0%. Concurrently, the median eGFR increased from 61.09 mL/min/1.73 m
conclusionAdd-on Telitacicept to standard supportive care may reduce proteinuria, improve renal function, and promote hematuria remission in patients with primary IgAN, with a favorable safety profile.
Indexed as
Identifiers
41870741What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.